modelB03XA02

Diagram of B03XA02

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:DarbepoetinAlfa
ATC code:B03XA02
route:intravenous
compartments:2
dosage:0.75mg
volume of distribution:4.9L
clearance:0.0458l/h/kg
other parameters in model implementation

Darbepoetin alfa is a synthetic analog of erythropoietin used to stimulate erythropoiesis. It is approved for the treatment of anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in cancer patients. It is longer-acting than recombinant human erythropoietin due to additional sialic acid groups.

Pharmacokinetics

Pharmacokinetic parameters in adults with chronic kidney disease after intravenous and subcutaneous administration. Subjects included both male and female patients, 18 to 75 years old, with stable renal function.

References

  1. An, G, et al., & Veng-Pedersen, P (2017). Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. Journal of pharmaceutical sciences 106(6) 1644–1649. DOI:10.1016/j.xphs.2017.02.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28189627

  2. Roberts, JK, et al., & Sherwin, CM (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clinical pharmacokinetics 54(12) 1237–1244. DOI:10.1007/s40262-015-0286-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25989868

  3. Agoram, B, et al., & Sullivan, JT (2007). Population pharmacokinetics of darbepoetin alfa in healthy subjects. British journal of clinical pharmacology 63(1) 41–52. DOI:10.1111/j.1365-2125.2006.02752.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16939525

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)